Q32 Bio Inc. has named Dr. José Trevejo as Chief Medical Officer and Dr. Ellie Hershberger as Chief Development Officer amid its transition to late-stage clinical development. The company is progressing its drug bempikibart, targeting severe alopecia areata, into a registration-directed program expected in early 2027. Bempikibart has shown promising results in hair regrowth and safety during Phase 2 trials. The appointments bring extensive expertise to support Q32 Bio's plans to expand development into other autoimmune diseases involving IL-7 and TSLP pathways.
PBF Energy's subsidiary, PBF Holding, intends to offer $500 million in exchangeable notes due 2032 in a private placement to qualified institutional buyers. The notes will be senior unsecured obligations, with interest paid semiannually, and can be e...
Kyndryl has finalized its acquisition of Healthcare IT Leaders for up to $350 million, enhancing its capabilities in healthcare IT services. This move combines Healthcare IT Leaders' consulting and managed services with Kyndryl's infrastructure and A...
Crude oil prices surged above $100 per barrel after drone attacks forced Saudi Arabia to shut its critical East-West pipeline, which carries about 4 million barrels per day to the Red Sea port of Yanbu. This pipeline outage threatens up to 4% of the ...
Broadcom's stock dropped 5% after missing Q4 revenue estimates but is forecasted to rally 51% in the next year, reaching a new all-time high. Analyst Vijay Rakesh from Mizuho Securities maintains a 'Buy' rating and a $530 price target, citing Broadco...
Fairview Health Services has become the first U.S. health system to deploy the BD Vmax 160, a next-generation pharmacy automation robot designed to handle the growing complexity of specialty therapies and refrigerated medications in centralized outpa...
